Similar Effects of the Selective Noradrenaline Reuptake Inhibitor Atomoxetine on Three Distinct Forms of Impulsivity in the Rat
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Atomoxetine is a noradrenaline-specific reuptake inhibitor used clinically for the treatment of childhood and adult attention deficit hyperactivity disorder (ADHD). Studies in human volunteers and patient groups have shown that atomoxetine improves stop-signal reaction time (SSRT) performance, an effect consistent with a reduction in motor impulsivity. However, ADHD is a heterogeneous disorder and it is of interest to determine whether atomoxetine is similarly effective against other forms of impulsivity, as well as the attentional impairment present in certain subtypes of ADHD. The present study examined the effects of atomoxetine on impulsivity using an analogous SSRT task in rats and two additional tests of impulsivity; delay discounting of reward and the five-choice serial reaction time task (5CSRTT), the latter providing an added assessment of sustained visual attention. Atomoxetine produced a significant dose-dependent speeding of SSRT. In addition, atomoxetine produced a selective, dose-dependent decrease in premature responding on the 5CSRTT. Finally, on the delay-discounting task, atomoxetine significantly decreased impulsivity by increasing preference for the large-value reward across increasing delay. These findings conclusively demonstrate that atomoxetine decreases several distinct forms of impulsivity in rats. The apparent contrast of these effects with stimulant drugs such as amphetamine and methylphenidate, which generally act to increase impulsivity on the 5CSRTT, may provide new insights into the mechanisms of action of stimulant and nonstimulant drugs in ADHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Atomoxetine improves measures of PFC cognitive function in rats (Newman et al., 2008; Robinson et al., 2008; Seu et al., 2009), monkeys (Gamo et al., 2010; Seu et al., 2009), and humans (Chamberlain et al., 2007; Chamberlain et al., 2006).”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Robinson et al., 2008
In the citing paper
“For example, atomoxetine, a relatively selective norepinephrine uptake inhibitor, improves response inhibition in both the 5-CRSTT and the stop-signal task (Robinson et al 2008).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Robinson et al 2008
Citations
Cites
On the ability to inhibit thought and action: a theory of an act of control
Logan, G. D., & Cowan, W. B. (1984) · Psychological Review · doi:10.1037/0033-295x.91.3.295 · Cited by 2,590 · cited 1×
“Recently, atomoxetine has been shown to improve performance in normal human volunteers in a stop-signal reaction time (SSRT) task (Chamberlain et al, 2006), which provides a measure of motor inhibition and the propensity toward behavioral impulsivity (Logan and Cowan, 1984).”
BackgroundInhibitory Processes in Attention, Memory and Language
Carr, T. H., & Dagenbach, D. (1994) · Medical Entomology and Zoology · Cited by 2,362
Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans
Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W. (2003) · Nature Neuroscience · doi:10.1038/nn1003 · Cited by 1,771 · cited 2×
“…rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org improved, in both humans and rodents, by stimulants such as methylphenidate (Tannock et al, 1989; Aron et al, 2003b; Eagle et al, 2007b) and by the anti-narcoleptic agent modafinil (Turner et al, 2003, 2004; Eagle et al, 2007b).”
BackgroundInfluentialSelf-citationPrefrontal executive and cognitive functions in rodents: neural and neurochemical substrates
Dalley, J. W., Cardinal, R. N., & Robbins, T. W. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.09.006 · Cited by 1,329 · cited 2×
“Subjects were trained to detect the location of a brief visual stimulus (0.5 s in duration) presented pseudorandomly in one of five apertures over a large number of trials, as described previously (Dalley et al, 2004).”
MethodInfluentialSelf-citationThe 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry
Robbins, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1154-7 · Cited by 1,282 · cited 3×
“The 5CSRTT also allows for the measurement of attentional capacity because of its requirement for rats to detect brief visual targets (Robbins, 2002).”
BackgroundMethodSelf-citationBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 7×
“Neuropsychopharmacology striatal DA (Bymaster et al, 2002).”
BackgroundInfluentialOn the ability to inhibit thought and action: A users' guide to the stop signal paradigm
Logan, G. D. (1994) · UvA-DARE (University of Amsterdam) · Cited by 1,115
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948 · cited 1×
“…with stimulant and nonstimulant medications have shown that atomoxetine, amphetamine, and methylphenidate all enhance DA and NA in the PFC (for review see Solanto, 1998; Arnsten and Li, 2005; Arnsten, 2006a, b) but atomoxetine does not increase DA in the nucleus accumbens (Bymaster et al, 2002).”
BackgroundImpulsive choice induced in rats by lesions of the nucleus accumbens core
Cardinal, R. N., Pennicott, D. R., Lakmali, C., Sugathapala, Robbins, T. W., & Everitt, B. J. (2001) · Science · doi:10.1126/science.1060818 · Cited by 923 · cited 1×
“For example, lesions of the nucleus accumbens core region impair delay discounting by enhancing impulsive choice (Cardinal et al, 2001) but have no effect on SSRT (Eagle and Robbins, 2003b).”
BackgroundSelf-citationRubia, K., Smith, A. B., Brammer, M. J., & Taylor, E. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00275-1 · Cited by 852 · cited 1×
“SSRT itself is especially susceptible to damage to the right inferior frontal cortex in humans (Aron et al, 2003a; Rubia et al, 2003), and in rats following damage to the ventral orbitofrontal cortex, but not the prelimbic or infralimbic prefrontal cortex (PFC) (Eagle and Robbins, 2003b; Eagle et…”
BackgroundWinstanley, C. A., Eagle, D. M., & Robbins, T. W. (2006) · Clinical Psychology Review · doi:10.1016/j.cpr.2006.01.001 · Cited by 842 · cited 2×
“However, depending on dose and precise testing conditions, amphetamine can either reduce or enhance impulsive choice in delayed discounting situations (Cardinal et al, 2000; Richards et al, 1999; Winstanley et al, 2006).”
BackgroundSelf-citationA Network Model of Catecholamine Effects: Gain, Signal-to-Noise Ratio, and Behavior
Servan-Schreiber, D., Printz, H., & Cohen, J. D. (1990) · Science · doi:10.1126/science.2392679 · Cited by 767 · cited 1×
“These effects appear contradictory when compared to data from the human literature where moderate doses of stimulants have been consistently shown to improve sustained attention and decrease impulsivity (Servan-Schreiber et al, 1990; Ward et al, 1997).”
ResultCarli, M., Robbins, T. W., Evenden, J. L., & Everitt, B. J. (1983) · Behavioural Brain Research · doi:10.1016/0166-4328(83)90138-9 · Cited by 736 · cited 1×
“A detailed description of the nine-hole apparatus (Carli et al, 1983) and procedures (Dalley et al, 2004) has been provided previously.”
MethodSelf-citationSolanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677 · cited 1×
“…with stimulant and nonstimulant medications have shown that atomoxetine, amphetamine, and methylphenidate all enhance DA and NA in the PFC (for review see Solanto, 1998; Arnsten and Li, 2005; Arnsten, 2006a, b) but atomoxetine does not increase DA in the nucleus accumbens (Bymaster et al, 2002).”
BackgroundEvenden, J. L., & Ryan, C. N. (1996) · Psychopharmacology · doi:10.1007/s002130050121 · Cited by 634 · cited 2×
“Experiments in animals, using both amphetamine and methylphenidate, have shown decreased impulsivity, ie increased choice of a larger delayed reward over a smaller immediate reward (Evenden and Ryan, 1996; van Gaalen et al, 2006).”
BackgroundResultBerridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617 · cited 14×
“The evaluation of ADHD medications using animal ‘models’ is not straightforward, since ADHD typically presents as a spectrum of disorders, and no animal ‘models’ replicate the full range of deficits found in ADHD (for discussion see Sagvolden et al, 2005; Russell et al, 2005).”
BackgroundInfluentialNeurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 3×
“Recently, atomoxetine has been shown to improve performance in normal human volunteers in a stop-signal reaction time (SSRT) task (Chamberlain et al, 2006), which provides a measure of motor inhibition and the propensity toward behavioral impulsivity (Logan and Cowan, 1984).”
BackgroundMethodResultSelf-citationGranon, S., Passetti, F., Thomas, K. L., Dalley, J. W., Everitt, B. J., & Robbins, T. W. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-03-01208.2000 · Cited by 546 · cited 1×
“Selective targeting of PFC catecholamine receptors has previously shown that activation of a2adrenoceptors and D1 DA receptors in the PFC contributes to the performance-enhancing effects of methylphenidate (Granon et al, 2000; Arnsten and Dudley, 2005).”
BackgroundSelf-citationImpaired inhibitory control of behavior in chronic cocaine users
Fillmore, M. T., & Rush, C. R. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00206-x · Cited by 519 · cited 2×
“Deficits in SSRT task performance are commonly found in disorders of behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine (Fillmore and Rush, 2002) o…”
BackgroundCognitive enhancing effects of modafinil in healthy volunteers
Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., & Sahakian, B. J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1250-8 · Cited by 515 · cited 1×
“…rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org improved, in both humans and rodents, by stimulants such as methylphenidate (Tannock et al, 1989; Aron et al, 2003b; Eagle et al, 2007b) and by the anti-narcoleptic agent modafinil (Turner et al, 2003, 2004; Eagle et al, 2007b).”
BackgroundInfluentialSelf-citationAttention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
Biederman, J., & Spencer, T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00192-4 · Cited by 513 · cited 1×
“…has generally been considered a disease of DA hypofunction (for discussion see Solanto, 2002), however, a role for NA should not be excluded given that the medications currently used to treat ADHD target some component of the noradrenergic system (Biederman and Spencer, 1999; Arnsten, 2006a, b).”
BackgroundStimulants: Therapeutic Actions in ADHD
Arnsten, A. F. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301164 · Cited by 473 · cited 2×
“…has generally been considered a disease of DA hypofunction (for discussion see Solanto, 2002), however, a role for NA should not be excluded given that the medications currently used to treat ADHD target some component of the noradrenergic system (Biederman and Spencer, 1999; Arnsten, 2006a, b).”
BackgroundDopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research
Solanto, M. V. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00431-4 · Cited by 455 · cited 1×
“ADHD has generally been considered a disease of DA hypofunction (for discussion see Solanto, 2002), however, a role for NA should not be excluded given that the medications currently used to treat ADHD target some component of the noradrenergic system (Biederman and Spencer, 1999; Arnsten, 2006a,…”
BackgroundHarrison, A. A., Everitt, B. J., & Robbins, T. W. (1997) · Psychopharmacology · doi:10.1007/s002130050410 · Cited by 452 · cited 1×
“Studies using the 5CSRTT have generally reported an increase in premature responding following administration of amphetamine or methylphenidate (Cole and Robbins, 1987, 1989; Harrison et al, 1997; Robbins, 2002).”
MethodSelf-citationRodent Models of Attention-Deficit/Hyperactivity Disorder
Sagvolden, T., Russell, V. A., Aase, H., Johansen, E. B., & Farshbaf, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.002 · Cited by 448 · cited 1×
“The evaluation of ADHD medications using animal ‘models’ is not straightforward, since ADHD typically presents as a spectrum of disorders, and no animal ‘models’ replicate the full range of deficits found in ADHD (for discussion see Sagvolden et al, 2005; Russell et al, 2005).”
BackgroundAcute administration of d-amphetamine decreases impulsivity in healthy volunteers
de Wit, H. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00343-3 · Cited by 436 · cited 1×
“Previous studies using amphetamine in healthy volunteers (de Wit et al, 2002) and rodents (Wade et al, 2000; Winstanley et al, 2003; van Gaalen et al, 2006) have shown increases in tolerance to delay in delay-discounting paradigms.”
BackgroundDeficits in response inhibition associated with chronic methamphetamine abuse
Monterosso, J. R., Aron, A. R., Cordova, X., Xu, J., & London, E. D. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.02.002 · Cited by 425 · cited 1×
“…behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine (Fillmore and Rush, 2002) or methamphetamine use (Monterosso et al, 2005).”
Stop-Signal Reaction-Time Task Performance: Role of Prefrontal Cortex and Subthalamic Nucleus
Eagle, D. M., Baunez, C., Hutcheson, D. M., Lehmann, O., Shah, A. P., & Robbins, T. W. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm044 · Cited by 404 · cited 8×
“Evaluation of both methylphenidate and modafinil in the SSRT task for rats revealed a similar profile to that observed for amphetamine with selective effects observed in slow-stopping animals (Eagle et al, 2007).”
BackgroundMethodResultInfluentialSelf-citationMethylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder
Aron, A. R., Dowson, J. H., Sahakian, B. J., & Robbins, T. W. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00609-7 · Cited by 391 · cited 2×
“…rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org improved, in both humans and rodents, by stimulants such as methylphenidate (Tannock et al, 1989; Aron et al, 2003b; Eagle et al, 2007b) and by the anti-narcoleptic agent modafinil (Turner et al, 2003, 2004; Eagle et al, 2007b).”
BackgroundInfluentialSelf-citationFundamentals of Attention-Deficit/Hyperactivity Disorder: Circuits and Pathways
Arnsten, A. F. T. (2006) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 378
Arnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Cardinal, R. N., Robbins, T. W., & Everitt, B. J. (2000) · Psychopharmacology · doi:10.1007/s002130000536 · Cited by 338 · cited 3×
“However, depending on dose and precise testing conditions, amphetamine can either reduce or enhance impulsive choice in delayed discounting situations (Cardinal et al, 2000; Richards et al, 1999; Winstanley et al, 2006).”
BackgroundMethodSelf-citationEffects of dopaminergic drugs on delayed reward as a measure of impulsive behavior in rats
de Wit, H., Wade, T. R., & Richards, J. B. (2000) · Psychopharmacology · doi:10.1007/s002130000402 · Cited by 333 · cited 2×
“A role for DA in mediating the effects of amphetamine and methylphenidate has been shown using selective drugs to block D1 or D2 DA receptors (Wade et al, 2000; van Gaalen et al, 2006).”
BackgroundWinstanley, C. A., Theobald, D. E. H., Dalley, J. W., & Robbins, T. W. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300610 · Cited by 330 · cited 2×
“Training was conducted over three phases with only slight modifications from experimental procedures previously described (Cardinal et al, 2000; Winstanley et al, 2005; see Mar and Robbins, 2007 for greater detail).”
BackgroundMethodSelf-citationKuczenski, R., & Segal, D. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-07264.2002 · Cited by 316 · cited 1×
“Low-dose oral methylphenidate has also been shown to reduce locomotor activity in rats suggesting that dose and route may be important factors in the response to stimulant medication (Kuczenski and Segal, 2002).”
BackgroundCole, B. J., & Robbins, T. W. (1989) · Behavioural Brain Research · doi:10.1016/s0166-4328(89)80048-8 · Cited by 314 · cited 4×
“In well-trained animals, stimulant drugs increase the vigor of responding with increased premature responses and decreased response latencies (Cole and Robbins, 1987, 1989).”
BackgroundMethodInfluentialSelf-citationTurner, D. C., Clark, L., Dowson, J., Robbins, T. W., & Sahakian, B. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.008 · Cited by 301 · cited 1×
“…rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org improved, in both humans and rodents, by stimulants such as methylphenidate (Tannock et al, 1989; Aron et al, 2003b; Eagle et al, 2007b) and by the anti-narcoleptic agent modafinil (Turner et al, 2003, 2004; Eagle et al, 2007b).”
BackgroundInfluentialSelf-citationEffects of methylphenidate on inhibitory control in hyperactive children
Tannock, R., Schachar, R. J., Carr, R. P., Chajczyk, D., & Logan, G. D. (1989) · Journal of Abnormal Child Psychology · doi:10.1007/bf00916508 · Cited by 290 · cited 1×
“…All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org improved, in both humans and rodents, by stimulants such as methylphenidate (Tannock et al, 1989; Aron et al, 2003b; Eagle et al, 2007b) and by the anti-narcoleptic agent modafinil (Turner et al, 2003, 2004; Eagle et al,…”
BackgroundInfluentialInhibition of ongoing responses in patients with Parkinson's disease
Gauggel, S., Rieger, M., & Feghoff, T.-A. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.016469 · Cited by 284 · cited 1×
“Deficits in SSRT task performance are commonly found in disorders of behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine…”
BackgroundEffects of d-Amphetamine and alcohol on a measure of behavioral inhibition in rats.
Feola, T. W., de Wit, H., & Richards, J. B. (2000) · Behavioral Neuroscience · doi:10.1037/0735-7044.114.4.838 · Cited by 278 · cited 4×
“Amphetamine increases SSRT in poor performing humans and animals (de Wit et al, 2000; Eagle and Robbins, 2003a; Feola et al, 2000).”
BackgroundResultInfluentialWinstanley, C. A., Dalley, J. W., Theobald, D. E. H., & Robbins, T. W. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1546-3 · Cited by 256 · cited 1×
“Previous studies using amphetamine in healthy volunteers (de Wit et al, 2002) and rodents (Wade et al, 2000; Winstanley et al, 2003; van Gaalen et al, 2006) have shown increases in tolerance to delay in delay-discounting paradigms.”
BackgroundSelf-citationEagle, D. M., & Robbins, T. W. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.6.1302 · Cited by 252 · cited 15×
“In the rat SSRT task, atomoxetine is the first known example of a drug that is effective at reducing SSRT in rats independent of baseline performance: D-amphetamine, modafinil, and methylphenidate all show baseline-dependent effects on SSRT (Feola et al, 2000; Eagle and Robbins, 2003a; Eagle et al, 2007).”
BackgroundMethodInfluentialSelf-citationCole, B. J., & Robbins, T. W. (1987) · Psychopharmacology · doi:10.1007/bf00216011 · Cited by 240 · cited 3×
“In well-trained animals, stimulant drugs increase the vigor of responding with increased premature responses and decreased response latencies (Cole and Robbins, 1987, 1989).”
BackgroundMethodSelf-citationBehavioral disinhibition requires dopamine receptor activation
van Gaalen, M. M., Brueggeman, R. J., Bronius, P. F. C., Schoffelmeer, A. N. M., & Vanderschuren, L. J. M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0396-1 · Cited by 238 · cited 6×
“A role for DA in mediating the effects of amphetamine and methylphenidate has been shown using selective drugs to block D1 or D2 DA receptors (Wade et al, 2000; van Gaalen et al, 2006).”
BackgroundResultInfluentialAnimal models of attention-deficit hyperactivity disorder
Russell, V. A., Sagvolden, T., & Johansen, E. B. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-9 · Cited by 234
Swanson, C. J., Perry, K. W., Koch-Krueger, S., Katner, J., Svensson, K. A., & Bymaster, F. P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.022 · Cited by 214 · cited 2×
“Atomoxetine (tomoxetine, LY 139603) is a selective noradrenaline (NA) reuptake blocker (Bymaster et al, 2002; Swanson et al, 2006) used clinically to treat both adult and childhood attention deficit hyperactivity disorder (ADHD) (Kratochvil et al, 2003, 2006; Wilens, 2006).”
BackgroundMechanism of action of agents used in attention-deficit/hyperactivity disorder.
Wilens, T. E. (2006) · PubMed · Cited by 208
Effects of methamphetamine on the adjusting amount procedure, a model of impulsive behavior in rats
Richards, J. B., Sabol, K. E., & de Wit, H. (1999) · Psychopharmacology · doi:10.1007/pl00005488 · Cited by 203 · cited 1×
“However, depending on dose and precise testing conditions, amphetamine can either reduce or enhance impulsive choice in delayed discounting situations (Cardinal et al, 2000; Richards et al, 1999; Winstanley et al, 2006).”
BackgroundEffects of d-Amphetamine and ethanol on a measure of behavioral inhibition in humans.
de Wit, H., Crean, J. P., & Richards, J. B. (2000) · Behavioral Neuroscience · doi:10.1037//0735-7044.114.4.830 · Cited by 199 · cited 1×
“Amphetamine increases SSRT in poor performing humans and animals (de Wit et al, 2000; Eagle and Robbins, 2003a; Feola et al, 2000).”
BackgroundRubia, K., Russell, T., Bullmore, E. T., Soni, W., Brammer, M. J., Simmons, A., Taylor, E., Andrew, C., Giampietro, V., & Sharma, T. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00173-0 · Cited by 178 · cited 1×
“…in disorders of behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine (Fillmore and Rush, 2002) or methamphetamine use…”
BackgroundEagle, D. M., Tufft, M. R. A., Goodchild, H. L., & Robbins, T. W. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0701-7 · Cited by 176 · cited 8×
“Evaluation of both methylphenidate and modafinil in the SSRT task for rats revealed a similar profile to that observed for amphetamine with selective effects observed in slow-stopping animals (Eagle et al, 2007).”
BackgroundMethodResultInfluentialSelf-citationBaunez, C., & Robbins, T. W. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00065-2 · Cited by 171 · cited 1×
“These effects have been shown to involve the nucleus accumbens (Cole and Robbins, 1989) and dorsal striatum, (Baunez and Robbins, 1999) respectively.”
BackgroundSelf-citationBoonstra, A. M., Kooij, J. J. S., Oosterlaan, J., Sergeant, J. A., & Buitelaar, J. K. (2005) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390490515757 · Cited by 157 · cited 1×
“Moreover, D-amphetamine and methylphenidate generally improve SSRT performance, although their effects can be baseline dependent (Boonstra et al, 2005; Feola et al, 2000; Eagle and Robbins, 2003a; Eagle et al, 2007b).”
BackgroundKRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000222788.34229.68 · Cited by 150 · cited 14×
“The evaluation of ADHD medications using animal ‘models’ is not straightforward, since ADHD typically presents as a spectrum of disorders, and no animal ‘models’ replicate the full range of deficits found in ADHD (for discussion see Sagvolden et al, 2005; Russell et al, 2005).”
BackgroundInfluentialEagle, D. M., & Robbins, T. W. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.022 · Cited by 147 · cited 14×
“By contrast, lesions of the medial striatum impair SSRT (Eagle and Robbins, 2003a) and enhance premature responding on the 5CSRTT (Rogers et al, 2001), while reducing impulsive choice (DM Eagle, unpublished observations).”
BackgroundMethodInfluentialSelf-citationDimensional Analysis of ADHD Subtypes in Rats
Blondeau, C., & Dellu-Hagedorn, F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.030 · Cited by 133 · cited 4×
“The overall effect did not reach the same level of significance seen in the SSRT task or induce reductions at the low doses previously reported in a 5CSRTT (Blondeau and Dellu-Hagedorn, 2006).”
BackgroundResultInfluentialRubia, K. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00437-5 · Cited by 128 · cited 2×
“Deficits in SSRT task performance are commonly found in disorders of behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine (Fillmore and Rush, 2002) o…”
BackgroundActs of control in schizophrenia: dissociating the components of inhibition
BADCOCK, J. C., MICHIE, P. T., JOHNSON, L., & COMBRINCK, J. (2002) · Psychological Medicine · doi:10.1017/s0033291701005128 · Cited by 121 · cited 1×
“…task performance are commonly found in disorders of behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine (Fillmore and Rush,…”
BackgroundPuumala, T., Ruotsalainen, S., Jäkälä, P., Koivisto, E., Riekkinen, P. J., & Sirviö, J. (1996) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1996.0060 · Cited by 120 · cited 1×
“Although the majority of studies with stimulant drugs demonstrate increases in impulsivity, there have been reports suggesting that low doses of methylphenidate reduce impulsive responding in a poor performing subgroup of rats (Puumala et al, 1996).”
BackgroundLapiz, M. D. S., Bondi, C. O., & Morilak, D. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301235 · Cited by 95 · cited 1×
“Moreover, a larger impact on prefrontal NA is observed when DMI is administered chronically (Lapiz et al, 2006) and it is possible that the doses administered of acute DMI produced insufficiently effective increases in NA levels.”
BackgroundKratochvil, C. J., Vaughan, B. S., Harrington, M. J., & Burke, W. J. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.7.1165 · Cited by 94 · cited 14×
“The evaluation of ADHD medications using animal ‘models’ is not straightforward, since ADHD typically presents as a spectrum of disorders, and no animal ‘models’ replicate the full range of deficits found in ADHD (for discussion see Sagvolden et al, 2005; Russell et al, 2005).”
BackgroundInfluentialEvenden, J. L. (1999) · Psychopharmacology · doi:10.1007/pl00005487 · Cited by 65 · cited 4×
“In summary, these findings demonstrate that atomoxetine reduces impulsive responding in behavioral tasks hypothesized to involve distinct neural processes (Evenden, 1999).”
BackgroundInfluentialDelay Discounting and Impulsive Choice in the Rat
Mar, A. C., & Robbins, T. W. (2007) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0822s39 · Cited by 58 · cited 2×
“Training was conducted over three phases with only slight modifications from experimental procedures previously described (Cardinal et al, 2000; Winstanley et al, 2005; see Mar and Robbins, 2007 for greater detail).”
MethodSelf-citationInhibitory control in Obsessive-Compulsive Disorder
Krikorian, R., Zimmerman, M. E., & Fleck, D. E. (2004) · Brain and Cognition · doi:10.1016/j.bandc.2004.02.038 · Cited by 46 · cited 1×
“…behavioral inhibition, such as ADHD, Parkinson’s disease (Gauggel et al, 2004), schizophrenia (Badcock et al, 2002; Rubia, 2002; Rubia et al, 2001), obsessivecompulsive disorder (Krikorian et al, 2004), and chronic cocaine (Fillmore and Rush, 2002) or methamphetamine use (Monterosso et al, 2005).”
Ward, A. S., Kelly, T. H., Foltin, R. W., & Fischman, M. W. (1997) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.5.2.130 · Cited by 36 · cited 1×
“These effects appear contradictory when compared to data from the human literature where moderate doses of stimulants have been consistently shown to improve sustained attention and decrease impulsivity (Servan-Schreiber et al, 1990; Ward et al, 1997).”
ResultBizot, J. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00519-4 · Cited by 26 · cited 1×
“For example, D-amphetamine impairs the ability to wait, as shown by its disruptive effects on DRL schedule performance (Bizot, 1998) and in increasing premature responding on the 5CSRTT (Cole and Robbins, 1987, 1989).”
Background
Cited by
Inhibition and impulsivity: behavioral and neural basis of response control
Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921
Self-citationImpulsivity, compulsivity, and top-down cognitive control
Dalley, J. W., Everitt, B. J., & Robbins, T. W. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.020 · Cited by 1,589
“…by other systems within the ventral striatum; although selective 5-HT depletion from this region fails to affect the measure (Fletcher et al., 2009), intra-accumbens 5-HT2A and 5-HT2C antagonists have opposite effects (blocking and increasing impulsivity, respectively) (Robinson et al., 2008a).”
Self-citationDrug addiction: updating actions to habits to compulsions ten years on
Everitt, B. J., & Robbins, T. W. (2016) · Annual Review of Psychology · doi:10.1146/annurev-psych-122414-033457 · Cited by 1,225
Self-citationNeurocognitive endophenotypes of impulsivity and compulsivity: Towards dimensional psychiatry
Robbins, T. W., Gillan, C. M., Smith, D. G., de Wit, S., & Ersche, K. D. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.009 · Cited by 1,003
Self-citationEveritt, B. J., Belin, D., Economidou, D., Pelloux, Y., Dalley, J. W., & Robbins, T. W. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0089 · Cited by 974
“This impulsivity we term ‘waiting impulsivity’, as it is related to impulsivity measured as an inability to tolerate delays of reinforcement (Robinson et al. 2008), but appears different from the response impulsivity measured by the stop-signal reaction time in STOPsignal reaction-time tasks (Eagle et al.”
MethodSelf-citation
Metadata
- Authors
- Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Eagle, Dawn M
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2007-07-18
- Volume
- 33
- Issue
- 5
- Pages
- 1028-1037
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1992488100
- Cited by
- 359
- References
- 66
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 16 · 2023: 11 · 2022: 15 · 2021: 17 · 2020: 13 · 2019: 10 · 2018: 18 · 2017: 21 · 2016: 21 · 2015: 20 · 2014: 37 · 2013: 23 · 2012: 25
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- Funders
- Wellcome Trust
- British Pharmacological Society
- Research Councils UK
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- atomoxetine, impulsivity, attention deficit hyperactivity disorder, norepinephrine reuptake inhibition, stop-signal reaction time, delay discounting, 5-choice serial reaction time task, visual attention, stimulants, amphetamine, methylphenidate, rats
- MeSH terms
- Atomoxetine Hydrochloride, Analysis of Variance, Animals, Behavior, Animal, Choice Behavior, Dose-Response Relationship, Drug, Impulsive Behavior, Inhibition, Psychological, Male, Propylamines, Reaction Time, Reinforcement, Psychology, Reinforcement Schedule, Task Performance and Analysis, Adrenergic Uptake Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.